Monopar Therapeutics is a biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. The company currently has three compounds in development: Validive, a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis in patients undergoing radiotherapy for oropharyngeal cancer, Camsirubicin, a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs, and MNPR-101, a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor for the treatment of advanced cancers.